PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
9719484-1	1998	Multidrug resistance-associated protein (MRP) causes multidrug resistance (MDR) involving the anthracyclines and epipodophyllotoxins.	Anthracyclines	94-108	ATP binding cassette subfamily C member 3	Homo sapiens	0-39	
27432453-0	2016	HDAC2 overexpression is a poor prognostic factor of breast cancer patients with increased multidrug resistance-associated protein expression who received anthracyclines therapy.	Anthracyclines	154-168	ATP binding cassette subfamily C member 3	Homo sapiens	90-129	
10792272-1	2000	We analysed the expression of three drug transporter proteins [p-glycoprotein (PGP), lung resistance-related protein (LRP) and multidrug resistance-associated protein (MRP1)] involved in anthracycline resistance that are frequently overexpressed in poor-risk adult acute non-lymphocytic leukaemia (ANLL), in 23 acute promyelocytic leukaemia (APL) patients at onset managed at a single institution.	Anthracyclines	187-200	ATP binding cassette subfamily C member 3	Homo sapiens	127-166	
15517899-0	2004	Multidrug resistance associated genes MRP1, MRP2 and MRP3 in primary and anthracycline exposed breast cancer.	Anthracyclines	73-86	ATP binding cassette subfamily C member 3	Homo sapiens	53-57	
9719484-1	1998	Multidrug resistance-associated protein (MRP) causes multidrug resistance (MDR) involving the anthracyclines and epipodophyllotoxins.	Anthracyclines	94-108	ATP binding cassette subfamily C member 3	Homo sapiens	41-44	
9719484-2	1998	Many studies show modulation of anthracycline levels and cytotoxicity in MRP-overexpressing cells, but there is limited data on the modulation of etoposide levels and cytotoxicity in MRP-overexpressing or in P-glycoprotein-expressing cells.	Anthracyclines	32-45	ATP binding cassette subfamily C member 3	Homo sapiens	73-76	
9334825-0	1997	Increased MRP expression is associated with resistance to radiation, anthracyclines and etoposide in cells treated with fractionated gamma-radiation.	Anthracyclines	69-83	ATP binding cassette subfamily C member 3	Homo sapiens	10-13	
9477189-11	1997	An increase in drug efflux via MRP, reduced topo II activity, and increased GSH levels/GSH-related enzyme activities may play major roles in nonPgP-mediated multidrug resistance in urothelial cancers treated with anthracyclines.	Anthracyclines	213-227	ATP binding cassette subfamily C member 3	Homo sapiens	31-34	
9120915-6	1997	Multi-drug resistance associated protein in this disease is induced more frequently by high dose (more than 300 mg.) than low dose (less than 300 mg.) anthracyclines (p < 0.01).	Anthracyclines	151-165	ATP binding cassette subfamily C member 3	Homo sapiens	0-40	
8626756-3	1996	Expression of both MRP and Mdr3 in the anthracycline hypersensitive mutant VASY2563 restored cellular resistance to Adriamycin in this mutant.	Anthracyclines	39-52	ATP binding cassette subfamily C member 3	Homo sapiens	19-22	
7805019-3	1995	Recently, transfection of HeLa cells with MRP expression vectors has demonstrated that the protein is capable of increasing resistance to natural product drugs such as anthracyclines, Vinca alkaloids, and epipodophyllotoxins (C. E. Grant et al., Cancer Res., 54: 357-361, 1994).	Anthracyclines	168-182	ATP binding cassette subfamily C member 3	Homo sapiens	42-45	
29090664-7	2018	In addition, genetic variability in the transporters of anthracyclines could affect the intake in cells, including influx (SLC28A3, SLC22A12, SLCO1B1) and efflux transporters (ABCB1, ABCC1, ABCC3, ABCG2).	Anthracyclines	56-70	ATP binding cassette subfamily C member 3	Homo sapiens	190-195